Results 11 to 20 of about 107,749 (252)
Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo [PDF]
Clinical, Cosmetic and Investigational Dermatology, 2019 Rehab M Samaka,1 Mohammed A Basha,2 Dina Menesy31Department of Pathology, Faculty of Medicine, Menoufia University, Shibīn al Kawm, Egypt; 2Department of Dermatology, Andrology and STDs, Faculty of Medicine, Menoufia University, Shibīn al Kawm, Egypt ...
Samaka RM, Basha MA, Menesy D
doaj +2 more sources
JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]
, 2016 The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana +5 more
core +14 more sources
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs
Molecular & Cellular Oncology, 2021 While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder +2 more
doaj +1 more source
Peripheral neuropathy associated with tofacitinib use in alopecia universalis
Journal of Dermatology and Dermatologic Surgery, 2022 Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss. Alopecia universalis (AU) is the advanced form of AA characterized by complete scalp and body hair loss.
Raghad Alharthi +4 more
doaj +1 more source
Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]
, 2019 Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran +2 more
core +1 more source
Janus kinase inhibitors: jackpot or potluck?
Oncology Reviews, 2012 The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat +1 more
doaj +1 more source
Successful treatment of pyoderma gangrenosum with Janus kinase 1/2 inhibition
JEADV Clinical Practice, 2022 Pyoderma gangrenosum (PG) is a rare, autoinflammatory disease leading to painful, hard‐to‐treat ulcers. Besides systemic glucocorticoids, a plethora of classic immunosuppressants, biologics and small molecules have been reported to improve PG disease ...
Sebastian Sitaru +2 more
doaj +1 more source
Changes of Signaling Pathways in Hypothalamic Neurons with Aging
Current Issues in Molecular Biology, 2023 The hypothalamus is an important regulator of autonomic and endocrine functions also involved in aging regulation. The aging process in the hypothalamus is accompanied by disturbed intracellular signaling including insulin/insulin-like growth factor-1 ...
Petr M. Masliukov
doaj +1 more source
TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death [PDF]
, 2019 BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas that arise most commonly in the setting of the Neurofibromatosis Type 1 (NF1) cancer predisposition syndrome.
Bu, Xianzhang +7 more
core +2 more sources
Janus kinase-1 and 3 in ankylosing spondylitis
Journal of the Formosan Medical Association, 2019 Background/purpose: To investigate the Janus kinase-1 and 3 (JAK-1 and 3) expression in peripheral blood mononuclear cells (PBMCs) in ankylosing spondylitis (AS). Methods: The levels of JAK-1 and JAK-3 mRNA in PBMCs, CD3+ T cells and CD14+ monocytes were
Hsien-Tzung Liao +7 more
doaj +1 more source